47.03

3.20% 1.46

After Hours: 47.03

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $47.03, with a volume of 3.27M. It is up +3.20% in the last 24 hours and up +4.16% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$45.57

Open:

$45.8

24h Volume:

3.27M

Relative Volume:

0.91

Market Cap:

$20.15B

Revenue:

$2.38B

Net Income/Loss:

$1.32B

P/E Ratio:

26.41

EPS:

1.7806

Net Cash Flow:

$897.24M

1W Performance:

+2.71%

1M Performance:

+4.16%

6M Performance:

+34.76%

1Y Performance:

+39.31%

1-Day Range:

$45.79

$47.08

1-Week Range:

$44.73

$47.08

52-Week Range:

$29.66

$47.86

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2026-02-11

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	47.03	19.52B	2.38B	1.32B	897.24M	1.7806
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	UBS	Neutral → Buy
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

05:14 AM

Royalty Pharma EVP Coyne sells shares worth $1.58 million - Investing.com

05:14 AM

05:05 AM

Royalty Pharma (RPRX) CFO’s entities sell 34,791 shares under 10b5-1 plan - Stock Titan

05:05 AM

09:03 AM

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance

09:03 AM

Mar 24, 2026

Nordea Investment Management AB Grows Position in Royalty Pharma PLC $RPRX - MarketBeat

Mar 24, 2026

Royalty Pharma names Lucas Glass as head of artificial intelligence By Investing.com - Investing.com India

Mar 24, 2026

Mar 23, 2026

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance UK

Mar 23, 2026

Affiliates of RPRX sell multiple blocks of common stock (RPRX) - Stock Titan

Mar 23, 2026

Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026 - marketscreener.com

Mar 23, 2026